Apexigen To Present At Upcoming Investor Conferences

SAN CARLOS, Calif., Feb. 19, 2019 /PRNewswire/ -- Apexigen, Inc., a clinical-stage biopharmaceutical company, today announced that Xiaodong Yang, M.D., Ph.D., President and Chief Executive Officer, will present at the following upcoming investor conferences:

Citi's 7th Annual Immuno-oncology Leadership SummitNew York, NYTuesday, February 19, 2019 at 3:30 pm ET

SVB Leerink's 8th Annual Global Healthcare ConferenceNew York, NYWednesday, February 27, 2019 at 2:10 pm ET

Cowen's 39th Annual Healthcare ConferenceBoston, MATuesday, March 12, 2019 at 4:00 pm ET

William Blair's IO ConferenceNew York, NYThursday, March 21, 2019 at 2:05 pm ET

About ApexigenApexigen is a clinical-stage biopharmaceutical company discovering and developing a new generation of antibody therapeutics for oncology, with an emphasis on new immuno-oncology agents that could harness the patient's immune system to combat and eradicate cancer. APX005M and Apexigen's additional preclinical programs were discovered using APXiMAB™, Apexigen's proprietary product discovery platform. This platform has enabled Apexigen and its collaboration partners to discover and develop high-quality therapeutic antibodies against a variety of molecular targets, including targets that are difficult to drug with conventional antibody technologies. Seven product candidates discovered using APXiMAB™ are currently in clinical development, either internally by Apexigen or by its partners. For more information, please visit www.apexigen.com.

Apexigen Contact:Mark NevinsVice President, Business Development650-931-6236[email protected]

View original content to download multimedia:http://www.prnewswire.com/news-releases/apexigen-to-present-at-upcoming-investor-conferences-300797562.html

SOURCE Apexigen, Inc.